{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T12:54:28Z","timestamp":1762520068017,"version":"3.40.2"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T00:00:00Z","timestamp":1332201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Mol Hist"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s10735-012-9400-8","type":"journal-article","created":{"date-parts":[[2012,3,19]],"date-time":"2012-03-19T01:03:29Z","timestamp":1332119009000},"page":"307-317","source":"Crossref","is-referenced-by-count":19,"title":["Effect of COX-2 inhibitor lumiracoxib and the TNF-\u03b1 antagonist etanercept on TNBS-induced colitis in Wistar rats"],"prefix":"10.1007","volume":"43","author":[{"given":"Ana Paula Ribeiro","family":"Paiotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Araki","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roseane Mendes","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcia","family":"Marchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celina Tizuko Fujiyama","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo Artigiani","family":"Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sender Jankiel","family":"Miszputen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,20]]},"reference":[{"key":"9400_CR1","first-page":"G119","volume":"269","author":"CB Appleyard","year":"1995","unstructured":"Appleyard CB, Wallace JL (1995) Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol 269:G119\u2013G125","journal-title":"Am J Physiol"},{"key":"9400_CR2","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.2223\/JPED.151","volume":"76","author":"D Barbieri","year":"2000","unstructured":"Barbieri D (2000) Inflammatory bowel diseases. J Pediatr (Rio J) 76:S173\u2013S180","journal-title":"J Pediatr (Rio J)"},{"key":"9400_CR3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/gast.2003.50045","volume":"124","author":"DK Bonen","year":"2003","unstructured":"Bonen DK, Cho JH (2003) The genetics of inflammatory bowel disease. Gastroenterology 124:521\u2013536","journal-title":"Gastroenterology"},{"key":"9400_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03009740310004766","volume":"33","author":"K Brune","year":"2004","unstructured":"Brune K, Hinz B (2004) Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol 33:1\u20136","journal-title":"Scand J Rheumatol"},{"key":"9400_CR5","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1046\/j.1365-2036.2001.01111.x","volume":"15","author":"S Colpaert","year":"2001","unstructured":"Colpaert S, Liu Z, De Greef B, Rutgeerts P, Ceuppens JL, Geboes K (2001a) Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indometacin-induced bowel inflammation rat model. Aliment Pharmacol Ther 15:1827\u20131836","journal-title":"Aliment Pharmacol Ther"},{"key":"9400_CR6","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1046\/j.1365-2036.2001.01111.x","volume":"15","author":"S Colpaert","year":"2001","unstructured":"Colpaert S, Liu Z, De Greef B, Rutgeerts P, Ceuppens JL, Geboes K (2001b) Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indometacin-induced bowel inflammation rat model. Aliment Pharmacol Ther 15:1827\u20131836","journal-title":"Aliment Pharmacol Ther"},{"key":"9400_CR7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s004320000225","volume":"127","author":"W Dempke","year":"2001","unstructured":"Dempke W, Rie C, Grothey A, Schmoll HJ (2001) Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127:411\u2013417","journal-title":"J Cancer Res Clin Oncol"},{"key":"9400_CR8","first-page":"1285","volume":"2","author":"A Dhar","year":"2003","unstructured":"Dhar A, Brindley JM, Stark C, Citro ML, Keefer LK, Colburn NH (2003) Nitric oxide does not mediate but inhibits transformation and tumor phenotype. Mol Cancer Ther 2:1285\u20131293","journal-title":"Mol Cancer Ther"},{"key":"9400_CR9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.bjp.0706979","volume":"150","author":"R Paola Di","year":"2007","unstructured":"Di Paola R, Mazzon E, Muia C, Crisafulli C, Terrana D, Greco S et al (2007) Effects of etanercept, a tumour necrosis factor-\u03b1 antagonist, in an experimental model of periodontitis in rats. Br J Pharmacol 150:286\u2013297","journal-title":"Br J Pharmacol"},{"key":"9400_CR10","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/0016-5085(95)90599-5","volume":"109","author":"CO \u00c9lson","year":"1995","unstructured":"\u00c9lson CO, Sartor RB, Tennyson GS, Riddell RH (1995) Experimental models of inflammatory bowel disease. Gastroenterology 109:1344\u20131367","journal-title":"Gastroenterology"},{"key":"9400_CR11","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.bjp.0706078","volume":"144","author":"R Esser","year":"2005","unstructured":"Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA, Haston W, Kimble EF, Koehler J, Peppard J, Quadros E, Quintavalla J, Toscano K, Urban L, Van Duzer J, Zhang X, Zhou S, Marshall PJ (2005) Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 144:538\u2013550","journal-title":"Br J Pharmacol"},{"key":"9400_CR12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/abbi.1993.1601","volume":"307","author":"L Feng","year":"1993","unstructured":"Feng L, Sun W, Xia Y, Tang WW, Chanmugam P, Soyoola E, Wilson CB, Hwang D (1993) Cloning two isoforms of rats cyclooxygenase: Differential regulation of their expression. Arch Biochem Biophys 307:361\u2013368","journal-title":"Arch Biochem Biophys"},{"key":"9400_CR13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7150\/ijms.5.169","volume":"5","author":"W Fries","year":"2008","unstructured":"Fries W, Muja C, Crisafulli C, Constantino G, Longo G, Cuzzocrea S et al (2008) Infliximab and etanercept are equally effective in reducing enterocyte apoptosis in experimental colitis. Int J Med Sci 5:169\u2013180","journal-title":"Int J Med Sci"},{"key":"9400_CR14","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/gut.2004.047092","volume":"53","author":"PR Gibson","year":"2004","unstructured":"Gibson PR (2004) Increased gut permeability in Crohn\u2019s disease: is TNF the link? Gut 53:1724\u20131725","journal-title":"Gut"},{"key":"9400_CR15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.49.3.443","volume":"49","author":"F Halter","year":"2001","unstructured":"Halter F, Tarnawski AS, Schmassmann A, Peskar BM (2001) Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 49:443\u2013453","journal-title":"Gut"},{"key":"9400_CR16","first-page":"1804","volume":"31","author":"CJ Hawkey","year":"2004","unstructured":"Hawkey CJ, Svoboda P, Fiedorowicz-Fabrycy IF, Nasonov EL, Pikhlak EG, Cousin M, Gitton X, Hoexter G (2004) Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis. J Rheum 31:1804\u20131810","journal-title":"J Rheum"},{"key":"9400_CR17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/gast.1996.v111.pm8690211","volume":"111","author":"S Kargman","year":"1996","unstructured":"Kargman S, Charlesion S, Cartwright M, Frank J, Riendeaw D, Mancini J, Evans J, O\u2019Neill G (1996) Characterization of prostaglandin G\/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111:445\u2013454","journal-title":"Gastroenterology"},{"key":"9400_CR18","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1365-2036.2004.01956.x","volume":"19","author":"AJ Kivitz","year":"2004","unstructured":"Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C (2004) Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther 19:1189\u20131198","journal-title":"Aliment Pharmacol Ther"},{"key":"9400_CR19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0889-8553(21)00206-5","volume":"24","author":"BA Lashner","year":"1995","unstructured":"Lashner BA (1995) Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 24:467\u2013474","journal-title":"Gastroenterol Clin North Am"},{"key":"9400_CR20","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0024-3205(03)00317-5","volume":"73","author":"JK Lee","year":"2003","unstructured":"Lee JK, Choi SS, Won JS, Suh WH (2003) The regulation of inducible nitric oxide synthase gene expression induced by lipopolysaccharide and tumor necrosis factor-alpha in C6 cells: involvement of AP-1 and NfkappaB. Life Sci 73:595\u2013609","journal-title":"Life Sci"},{"key":"9400_CR21","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/jama.284.10.1297","volume":"284","author":"DR Lichtenstein","year":"2000","unstructured":"Lichtenstein DR, Wolfe MM (2000) COX-2 selective NSAIDS. New and improved? J Am Med Assoc 284:1297\u20131299","journal-title":"J Am Med Assoc"},{"key":"9400_CR22","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cellsig.2003.10.002","volume":"16","author":"CC Lin","year":"2004","unstructured":"Lin CC, Hsiao LD, Chien CS, Lee CW, Hsieh JT, Yang CM (2004) Tumor necrosis factor-alpha-induced cyclooxygenase-2 expression in human tracheal smooth muscle cells: involvement of p42\/p44 and p38 mitogen-activated protein kinases and nuclear factor-kappaB. Cell Signal 16:597\u2013607","journal-title":"Cell Signal"},{"key":"9400_CR23","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1572-0241.2002.05608.x","volume":"97","author":"U Mahadevan","year":"2001","unstructured":"Mahadevan U, Loftus EV, Tremaine WJ (2001) Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 97:910\u2013914","journal-title":"Am J Gastroenterol"},{"key":"9400_CR24","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1124\/dmd.32.5.566","volume":"32","author":"JB Mangold","year":"2004","unstructured":"Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C (2004) Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Dispos 32:566\u2013571","journal-title":"Drug Metab Dispos"},{"key":"9400_CR25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/gast.1997.v112.pm9024292","volume":"112","author":"H Mizuno","year":"1997","unstructured":"Mizuno H, Akamatsu T, Kasuga M (1997) Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112:387\u2013397","journal-title":"Gastroenterology"},{"key":"9400_CR26","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0016-5085(89)80079-4","volume":"96","author":"GP Morris","year":"1989","unstructured":"Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL (1989) Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795\u2013803","journal-title":"Gastroenterology"},{"key":"9400_CR27","first-page":"156","volume":"330","author":"GP O\u2019Neill","year":"1993","unstructured":"O\u2019Neill GP, Ford-Hutchinson AW (1993) Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 330:156\u2013160","journal-title":"FEBS Lett"},{"key":"9400_CR28","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s10620-006-9597-z","volume":"52","author":"M Okayama","year":"2007","unstructured":"Okayama M, Hayashi S, Aoi Y, Nishio H, Kato S, Takeuchi K (2007) Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats. Dig Dis Sci 52:2095\u20132103","journal-title":"Dig Dis Sci"},{"key":"9400_CR29","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1590\/S0100-879X2006005000128","volume":"40","author":"AP Paiotti","year":"2007","unstructured":"Paiotti AP, Artigiani-Neto R, Forones NM, Oshima CTF, Miszputen SJ, Franco M (2007) Immunoexpression of cyclooxygenase-1 and -2 in ulcerative colitis. Braz J Med Biol Res 40:911\u2013918","journal-title":"Braz J Med Biol Res"},{"key":"9400_CR30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10735-011-9349-z","volume":"42","author":"AP Paiotti","year":"2011","unstructured":"Paiotti AP, Miszputen SJ, Oshima CT, Artigiani Neto R, Ribeiro DA, Franco M (2011) Etanercept attenuates TNBS-induced experimental colitis: role of TNF-\u03b1 expression. J Mol Histol 42:443\u2013450","journal-title":"J Mol Histol"},{"key":"9400_CR31","first-page":"5185","volume":"11","author":"L Peran","year":"2005","unstructured":"Peran L, Camuesco D, Comalada M, Nieto A, Concha A, Diaz-Ropero MP et al (2005) Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis. World J Gastroenterol 11:5185\u20135192","journal-title":"World J Gastroenterol"},{"key":"9400_CR32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMra020831","volume":"347","author":"DK Podolsky","year":"2002","unstructured":"Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417\u2013429","journal-title":"N Engl J Med"},{"key":"9400_CR33","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1172\/JCI119013","volume":"98","author":"BK Reuter","year":"1996","unstructured":"Reuter BK, Asfaha S, Buret A et al (1996) Exacerbation of inflammatory associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 98:2076\u20132085","journal-title":"J Clin Invest"},{"key":"9400_CR34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1365-2036.2003.01691.x","volume":"18","author":"C Rordorf","year":"2003","unstructured":"Rordorf C, Kellett N, Mair S et al (2003) Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: a pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther 18:533\u2013541","journal-title":"Aliment Pharmacol Ther"},{"key":"9400_CR35","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/ibd.20005","volume":"13","author":"C Shen","year":"2007","unstructured":"Shen C, Hertogh G, Bullens DMA, Assche GV, Geboes K, Rutgeerts P et al (2007a) Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: Mechanisms beyond neutralization? Inflamm Bowel Dis 13:308\u2013316","journal-title":"Inflamm Bowel Dis"},{"key":"9400_CR36","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/ibd.20005","volume":"13","author":"C Shen","year":"2007","unstructured":"Shen C, Hertogh G, Bullens DMA, Assche GV, Geboes K, Rutgeerts P et al (2007b) Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: mechanisms beyond neutralization? Inflamm Bowel Dis 13:308\u2013316","journal-title":"Inflamm Bowel Dis"},{"key":"9400_CR37","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0022-3565(24)37734-1","volume":"286","author":"J Shigeta","year":"1998","unstructured":"Shigeta J, Takahashi S, Okabe S (1998) Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J Pharmacol Exp Ther 286:1383\u20131390","journal-title":"J Pharmacol Exp Ther"},{"key":"9400_CR38","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/BF02231636","volume":"17","author":"RG Shorter","year":"1972","unstructured":"Shorter RG, Huizenga KA, Spencer RJ, Guy SK (1972) Inflammatory bowel disease. The role of lymphotoxin in the cytotoxicity of lymphocytes for colonic epithelial cells. Am J Dig Dis 17:689\u2013696","journal-title":"Am J Dig Dis"},{"key":"9400_CR39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0016-5085(98)70196-9","volume":"115","author":"II Singer","year":"1998","unstructured":"Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF (1998) Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115:297\u2013306","journal-title":"Gastroenterology"},{"key":"9400_CR40","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/gut.41.3.344","volume":"41","author":"S Somasundaram","year":"1997","unstructured":"Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M, Price AB, Macpherson A, Mahmod T, Scott D, Wrigglesworth JM, Bjarnason I (1997) Mitochondrial damage: a possible mechanism of the \u201ctopical\u201d phase of NSAID induced injury to the rat intestine. Gut 41:344\u2013353","journal-title":"Gut"},{"key":"9400_CR41","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1111\/j.1572-0241.2002.05914.x","volume":"97","author":"P Suenaert","year":"2002","unstructured":"Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G et al (2002) Anti-tumor necrosis factor treatment restores the gut barrier in Crohn\u2019s disease. Am J Gastroenterol 97:2000\u20132004","journal-title":"Am J Gastroenterol"},{"key":"9400_CR42","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/01.MIB.0000168371.87283.4b","volume":"11","author":"P Suenaert","year":"2005","unstructured":"Suenaert P, Bulteel V, Vermeire S, Noman M, Van Assche G, Rutgeerts P (2005a) Hyperresponsiveness of the mucosal barrier in Crohn\u2019s disease is not tumor necrosis factor-dependent. Inflamm Bowel Dis 11:667\u2013673","journal-title":"Inflamm Bowel Dis"},{"key":"9400_CR43","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/01.MIB.0000168371.87283.4b","volume":"11","author":"P Suenaert","year":"2005","unstructured":"Suenaert P, Bulteel V, Vermeire S, Noman M, Van Assche G, Rutgeerts P (2005b) Hyperresponsiveness of the mucosal barrier in Crohn\u2019s disease is not tumor necrosis factor-dependent. Inflamm Bowel Dis 11:667\u2013673","journal-title":"Inflamm Bowel Dis"},{"key":"9400_CR44","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1023\/A:1018846912032","volume":"43","author":"H Ukawa","year":"1998","unstructured":"Ukawa H, Yamakuni H, Kato S, Takeuchi K (1998) Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs on gastric ulcerogenic and healing responses in experimental animals. Dig Dis Sci 43:2003\u20132011","journal-title":"Dig Dis Sci"},{"key":"9400_CR45","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3748\/wjg.v11.i8.1105","volume":"11","author":"B Xiong","year":"2005","unstructured":"Xiong B, Sun TJ, Hu WD, Cheng FL, Mao M, Zhou YF (2005) Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance. World J Gastroenterol 11:1105\u20131108","journal-title":"World J Gastroenterol"},{"key":"9400_CR46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1443-9573.2004.00164.x","volume":"5","author":"L Zhang","year":"2004","unstructured":"Zhang L, Lu YM, Dong XY (2004) Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid. Chin J Dig Dis 5:110\u2013114","journal-title":"Chin J Dig Dis"},{"key":"9400_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/MI\/2006\/92642","volume":"92642","author":"YH Zhou","year":"2006","unstructured":"Zhou YH, Yu JP, Liu YF, Teng XJ, Ming M, Lv P (2006) Effects of ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-\u03b1, NF-\u03baBp65, IL-6) in TNBS-induced colitis in rats. Mediators Inflamm 92642:1\u20139","journal-title":"Mediators Inflamm"}],"container-title":["Journal of Molecular Histology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-012-9400-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10735-012-9400-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-012-9400-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T13:03:24Z","timestamp":1742735004000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10735-012-9400-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,20]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["9400"],"URL":"https:\/\/doi.org\/10.1007\/s10735-012-9400-8","relation":{},"ISSN":["1567-2379","1567-2387"],"issn-type":[{"type":"print","value":"1567-2379"},{"type":"electronic","value":"1567-2387"}],"subject":[],"published":{"date-parts":[[2012,3,20]]}}}